298 related articles for article (PubMed ID: 30503705)
1. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.
Ott CJ; Federation AJ; Schwartz LS; Kasar S; Klitgaard JL; Lenci R; Li Q; Lawlor M; Fernandes SM; Souza A; Polaski D; Gadi D; Freedman ML; Brown JR; Bradner JE
Cancer Cell; 2018 Dec; 34(6):982-995.e7. PubMed ID: 30503705
[TBL] [Abstract][Full Text] [Related]
2. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.
Brown JD; Lin CY; Duan Q; Griffin G; Federation A; Paranal RM; Bair S; Newton G; Lichtman A; Kung A; Yang T; Wang H; Luscinskas FW; Croce K; Bradner JE; Plutzky J
Mol Cell; 2014 Oct; 56(2):219-231. PubMed ID: 25263595
[TBL] [Abstract][Full Text] [Related]
3. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
4. Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks.
Mallm JP; Iskar M; Ishaque N; Klett LC; Kugler SJ; Muino JM; Teif VB; Poos AM; Großmann S; Erdel F; Tavernari D; Koser SD; Schumacher S; Brors B; König R; Remondini D; Vingron M; Stilgenbauer S; Lichter P; Zapatka M; Mertens D; Rippe K
Mol Syst Biol; 2019 May; 15(5):e8339. PubMed ID: 31118277
[TBL] [Abstract][Full Text] [Related]
5. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
[TBL] [Abstract][Full Text] [Related]
6. Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism.
Kandaswamy R; Sava GP; Speedy HE; Beà S; Martín-Subero JI; Studd JB; Migliorini G; Law PJ; Puente XS; Martín-García D; Salaverria I; Gutiérrez-Abril J; López-Otín C; Catovsky D; Allan JM; Campo E; Houlston RS
Cell Rep; 2016 Aug; 16(8):2061-2067. PubMed ID: 27524613
[TBL] [Abstract][Full Text] [Related]
7. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia.
Lai TH; Ozer HG; Gasparini P; Nigita G; Distefano R; Yu L; Ravikrishnan J; Yilmaz S; Gallegos J; Shukla S; Puduvalli V; Woyach J; Lapalombella R; Blachly J; Byrd JC; Sampath D
Blood Adv; 2023 Jun; 7(12):2897-2911. PubMed ID: 36287107
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci.
Yan H; Tian S; Kleinstern G; Wang Z; Lee JH; Boddicker NJ; Cerhan JR; Kay NE; Braggio E; Slager SL
Hum Mol Genet; 2020 Sep; 29(16):2761-2774. PubMed ID: 32744316
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
Kasar S; Underbayev C; Yuan Y; Hanlon M; Aly S; Khan H; Chang V; Batish M; Gavrilova T; Badiane F; Degheidy H; Marti G; Raveche E
Oncogene; 2014 Jun; 33(25):3307-15. PubMed ID: 23995789
[TBL] [Abstract][Full Text] [Related]
10. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
11. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
[TBL] [Abstract][Full Text] [Related]
12. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia.
Huang D; Ovcharenko I
BMC Genomics; 2017 Mar; 18(1):236. PubMed ID: 28302063
[TBL] [Abstract][Full Text] [Related]
14. BET-bromodomain inhibitors modulate epigenetic patterns at the diacylglycerol kinase alpha enhancer associated with radiation-induced fibrosis.
Valinciute G; Weigel C; Veldwijk MR; Oakes CC; Herskind C; Wenz F; Plass C; Schmezer P; Popanda O
Radiother Oncol; 2017 Oct; 125(1):168-174. PubMed ID: 28916223
[TBL] [Abstract][Full Text] [Related]
15. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
Raisner R; Kharbanda S; Jin L; Jeng E; Chan E; Merchant M; Haverty PM; Bainer R; Cheung T; Arnott D; Flynn EM; Romero FA; Magnuson S; Gascoigne KE
Cell Rep; 2018 Aug; 24(7):1722-1729. PubMed ID: 30110629
[TBL] [Abstract][Full Text] [Related]
16. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
[TBL] [Abstract][Full Text] [Related]
17. BET inhibition disrupts transcription but retains enhancer-promoter contact.
Crump NT; Ballabio E; Godfrey L; Thorne R; Repapi E; Kerry J; Tapia M; Hua P; Lagerholm C; Filippakopoulos P; Davies JOJ; Milne TA
Nat Commun; 2021 Jan; 12(1):223. PubMed ID: 33431820
[TBL] [Abstract][Full Text] [Related]
18. A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation.
Llimos G; Gardeux V; Koch U; Kribelbauer JF; Hafner A; Alpern D; Pezoldt J; Litovchenko M; Russeil J; Dainese R; Moia R; Mahmoud AM; Rossi D; Gaidano G; Plass C; Lutsik P; Gerhauser C; Waszak SM; Boettiger A; Radtke F; Deplancke B
Nat Commun; 2022 Apr; 13(1):2042. PubMed ID: 35440565
[TBL] [Abstract][Full Text] [Related]
19. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
20. STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo.
Lin F; Wu D; Fang D; Chen Y; Zhou H; Ou C
Inflamm Res; 2019 Sep; 68(9):739-749. PubMed ID: 31218443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
